Hospital returns under drug diversion act
FDA is expected to issue a guidance letter by the end of the month. FDA will reportedly further liberalize an exemption for returns from the Prescription Drug Marketing Act's hospital resale ban. In a Nov. 3, 1988 guidance, the agency said hospital returns constitute banned resales unless the reason for returns are misshipment or misorder and they occur within 10 days of delivery.
You may also be interested in...
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
After a high-profile launch early this year, first-mover Perrigo has recalled its albuterol sulfate aerosol in the US following complaints of inhalers failing to dispense due to “clogging.” The firm has revealed the expected financial impact of the move as well as commenting on how long it expects the product to be off the market, during which albuterol rivals Cipla and Lupin could benefit.
Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.